Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study
- Author
- GRAY, Glenda E1 2 ; MOODIE, Zoe3 ; MNGADI, Kathryn7 ; INNES, Craig5 ; MATHEBULA, Matsontso6 ; ALLEN, Mary8 ; MCELRATH, M. Julie3 ; ROBERTSON, Michael9 ; KUBLIN, James3 ; COREY, Lawrence3 ; METCH, Barbara3 ; GILBERT, Peter B3 ; BEKKER, Linda-Gail4 ; CHURCHYARD, Gavin5 ; NCHABELENG, Maphoshane6 ; MLISANA, Koleka7 ; LAHER, Fatima1 ; ROUX, Surita4
[1] Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa
[2] South African Medical Research Council, Cape Town, South Africa
[3] Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States
[4] Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa
[5] Aurum Institute for Health Research, Johannesburg, South Africa
[6] MEDUNSA HIV Clinical Research Unit, University of Limpopo, Mankweng-E, South Africa
[7] Centre for AIDS Programme for Research in South Africa, University of KwaZulu-Natal, Durban, South Africa
[8] Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States
[9] Infectious Diseases and Vaccines Clinical Research, Merck and Company, North Wales, PA, United States
HVTN 503/Phambili study team - Source
Lancet. Infectious diseases (print). 2014, Vol 14, Num 5, pp 388-396, 9 p ; ref : 37 ref
- ISSN
- 1473-3099
- Scientific domain
- General medicine general surgery; Microbiology, infectious diseases
- Publisher
- Lancet Publishing Group, London
- Publication country
- United Kingdom
- Document type
- Article
- Language
- English
- Keyword (fr)
- Adénovirus 5 Immunoprophylaxie Long terme Prévention SIDA Vaccin Virus immunodéficience humaine Protéine Gag Afrique du Sud Adenoviridae Adénovirus humain Immunodéficit Immunopathologie Infection Lentivirus Mastadenovirus Retroviridae Virose Virus Afrique
- Keyword (en)
- Adenovirus 5 Immunoprophylaxis Long term Prevention AIDS Vaccine Human immunodeficiency virus South Africa Adenoviridae Human adenovirus Immune deficiency Immunopathology Infection Lentivirus Mastadenovirus Retroviridae Viral disease Virus Africa
- Keyword (es)
- Adenovirus 5 Inmunoprofilaxia Largo plazo Prevención SIDA Vacuna Human immunodeficiency virus Sudáfrica Adenoviridae Human adenovirus Inmunodeficiencia Inmunopatología Infección Lentivirus Mastadenovirus Retroviridae Virosis Virus Africa
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B05 Infectious diseases / 002B05C Viral diseases / 002B05C02 Human viral diseases / 002B05C02D Viral diseases of the lymphoid tissue and the blood. Aids
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B06 Immunopathology / 002B06D Immunodeficiencies. Immunoglobulinopathies / 002B06D01 Immunodeficiencies
- Discipline
- Immunopathology Infectious pathology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 28410359
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/S1473-3099(14)70020-9 
https://dx.doi.org/10.1016/S1473-3099(14)70020-9
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70020-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:141:\"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"388\";s:8:\"\u0000*\u0000epage\";s:3:\"396\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"GRAY\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Glenda E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:11:\"MOODIE, Zoe\";i:1;s:15:\"MNGADI, Kathryn\";i:2;s:12:\"INNES, Craig\";i:3;s:20:\"MATHEBULA, Matsontso\";i:4;s:11:\"ALLEN, Mary\";i:5;s:18:\"MCELRATH, M. Julie\";i:6;s:18:\"ROBERTSON, Michael\";i:7;s:13:\"KUBLIN, James\";i:8;s:15:\"COREY, Lawrence\";i:9;s:14:\"METCH, Barbara\";i:10;s:16:\"GILBERT, Peter B\";i:11;s:18:\"BEKKER, Linda-Gail\";i:12;s:17:\"CHURCHYARD, Gavin\";i:13;s:22:\"NCHABELENG, Maphoshane\";i:14;s:15:\"MLISANA, Koleka\";i:15;s:13:\"LAHER, Fatima\";i:16;s:12:\"ROUX, Surita\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:141:\"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70020-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:141:\"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"388\";s:8:\"\u0000*\u0000epage\";s:3:\"396\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"GRAY\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Glenda E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:11:\"MOODIE, Zoe\";i:1;s:15:\"MNGADI, Kathryn\";i:2;s:12:\"INNES, Craig\";i:3;s:20:\"MATHEBULA, Matsontso\";i:4;s:11:\"ALLEN, Mary\";i:5;s:18:\"MCELRATH, M. Julie\";i:6;s:18:\"ROBERTSON, Michael\";i:7;s:13:\"KUBLIN, James\";i:8;s:15:\"COREY, Lawrence\";i:9;s:14:\"METCH, Barbara\";i:10;s:16:\"GILBERT, Peter B\";i:11;s:18:\"BEKKER, Linda-Gail\";i:12;s:17:\"CHURCHYARD, Gavin\";i:13;s:22:\"NCHABELENG, Maphoshane\";i:14;s:15:\"MLISANA, Koleka\";i:15;s:13:\"LAHER, Fatima\";i:16;s:12:\"ROUX, Surita\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:141:\"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70020-9\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70020-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:141:\"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"388\";s:8:\"\u0000*\u0000epage\";s:3:\"396\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"GRAY\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Glenda E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:11:\"MOODIE, Zoe\";i:1;s:15:\"MNGADI, Kathryn\";i:2;s:12:\"INNES, Craig\";i:3;s:20:\"MATHEBULA, Matsontso\";i:4;s:11:\"ALLEN, Mary\";i:5;s:18:\"MCELRATH, M. Julie\";i:6;s:18:\"ROBERTSON, Michael\";i:7;s:13:\"KUBLIN, James\";i:8;s:15:\"COREY, Lawrence\";i:9;s:14:\"METCH, Barbara\";i:10;s:16:\"GILBERT, Peter B\";i:11;s:18:\"BEKKER, Linda-Gail\";i:12;s:17:\"CHURCHYARD, Gavin\";i:13;s:22:\"NCHABELENG, Maphoshane\";i:14;s:15:\"MLISANA, Koleka\";i:15;s:13:\"LAHER, Fatima\";i:16;s:12:\"ROUX, Surita\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:141:\"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70020-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:141:\"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"388\";s:8:\"\u0000*\u0000epage\";s:3:\"396\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"GRAY\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Glenda E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:11:\"MOODIE, Zoe\";i:1;s:15:\"MNGADI, Kathryn\";i:2;s:12:\"INNES, Craig\";i:3;s:20:\"MATHEBULA, Matsontso\";i:4;s:11:\"ALLEN, Mary\";i:5;s:18:\"MCELRATH, M. Julie\";i:6;s:18:\"ROBERTSON, Michael\";i:7;s:13:\"KUBLIN, James\";i:8;s:15:\"COREY, Lawrence\";i:9;s:14:\"METCH, Barbara\";i:10;s:16:\"GILBERT, Peter B\";i:11;s:18:\"BEKKER, Linda-Gail\";i:12;s:17:\"CHURCHYARD, Gavin\";i:13;s:22:\"NCHABELENG, Maphoshane\";i:14;s:15:\"MLISANA, Koleka\";i:15;s:13:\"LAHER, Fatima\";i:16;s:12:\"ROUX, Surita\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:141:\"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/S1473-3099(14)70020-9\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:141:\"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study\";s:9:\"\u0000*\u0000jtitle\";s:35:\"Lancet. Infectious diseases (print)\";s:9:\"\u0000*\u0000stitle\";s:28:\"Lancet. Infect. dis. (print)\";s:7:\"\u0000*\u0000date\";s:4:\"2014\";s:9:\"\u0000*\u0000volume\";s:2:\"14\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"388\";s:8:\"\u0000*\u0000epage\";s:3:\"396\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"1473-3099\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"GRAY\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Glenda E\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:17:{i:0;s:11:\"MOODIE, Zoe\";i:1;s:15:\"MNGADI, Kathryn\";i:2;s:12:\"INNES, Craig\";i:3;s:20:\"MATHEBULA, Matsontso\";i:4;s:11:\"ALLEN, Mary\";i:5;s:18:\"MCELRATH, M. Julie\";i:6;s:18:\"ROBERTSON, Michael\";i:7;s:13:\"KUBLIN, James\";i:8;s:15:\"COREY, Lawrence\";i:9;s:14:\"METCH, Barbara\";i:10;s:16:\"GILBERT, Peter B\";i:11;s:18:\"BEKKER, Linda-Gail\";i:12;s:17:\"CHURCHYARD, Gavin\";i:13;s:22:\"NCHABELENG, Maphoshane\";i:14;s:15:\"MLISANA, Koleka\";i:15;s:13:\"LAHER, Fatima\";i:16;s:12:\"ROUX, Surita\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:141:\"Recombinant adenovirus type 5 HIV gag\/pol\/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503\/Phambili study\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:23:\"Lancet Publishing Group\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"9\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
